Current evidence on the relationships among five polymorphisms in the matrix metalloproteinases genes and prostate cancer risk.
Humans
Male
Prostatic Neoplasms
/ genetics
Genetic Predisposition to Disease
Polymorphism, Single Nucleotide
Matrix Metalloproteinase 9
/ genetics
Matrix Metalloproteinase 2
/ genetics
Matrix Metalloproteinases
/ genetics
Risk Factors
Matrix Metalloproteinase 7
/ genetics
Matrix Metalloproteinase 1
/ genetics
Matrix metalloproteinases (MMPs)
Meta-analysis
Polymorphism
Prostate cancer
Tumor marker
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
18 May 2024
18 May 2024
Historique:
received:
02
01
2024
accepted:
13
05
2024
medline:
19
5
2024
pubmed:
19
5
2024
entrez:
18
5
2024
Statut:
epublish
Résumé
Matrix metalloproteinases (MMPs) had a variety of subtypes, which may be related to tumor invasion and angiogenesis, and the polymorphisms from MMPs have been also associated with the susceptibility to a variety of tumors, including prostate cancer (PCa). However, previous studies have not systematically analyzed the association between MMP and prostate cancer, so we conducted systematic data collection and analyzed to evaluate the relationship among polymorphisms in MMPs and PCa susceptibility. We searched PubMed, Web of Science, Embase and Google Scholar for all papers published up to Apr 3rd, 2023, and systematically analyzed the relationship among MMP1-1607 2G/1G, MMP2-1306 T/C, MMP2-735 T/C, MMP7-181 G/A, MMP9-1562 T/C and PCa susceptibility using multiple comparative models and subgroup analyses. We found that MMP2-1306 T/C polymorphism showed associations with PCa susceptibility, with the Ethnicity subgroup (Asian) being more pronounced. Similarly, MMP9-1562 T/C has also had associations with PCa susceptibility. Our current study found that the polymorphisms of, MMP2-1306 T/C, and MMP9-1562 T/C had strong associations with PCa risk.
Identifiants
pubmed: 38762659
doi: 10.1038/s41598-024-62016-z
pii: 10.1038/s41598-024-62016-z
doi:
Substances chimiques
MMP9 protein, human
0
MMP2 protein, human
0
Types de publication
Journal Article
Meta-Analysis
Langues
eng
Sous-ensembles de citation
IM
Pagination
11355Subventions
Organisme : the National Natural Science Foundation
ID : No. 81802576
Organisme : Wuxi Commission of Health and Family Planning
ID : No. T202102, Z202011, M202330
Organisme : Research topic of Jiangsu Health Commission
ID : Z2022047
Organisme : Talent plan of Taihu Lake in Wuxi (Double Hundred Medical Youth Professionals Program) from Health Committee of Wuxi
ID : No. BJ2020061, BJ2023051
Organisme : the Clinical trial of Affiliated Hospital of Jiangnan University
ID : No. LCYJ202227, LCYJ202323
Organisme : Health Committee of Wuxi
ID : No. BJ2020061, BJ2023051
Informations de copyright
© 2024. The Author(s).
Références
Siegel, R. L., Miller, K. D., Wagle, N. S. & Jemal, A. Cancer statistics, 2023. CA Cancer J. Clin. 73, 17–48 (2023).
pubmed: 36633525
doi: 10.3322/caac.21763
Cao, W., Chen, H.-D., Yu, Y.-W., Li, N. & Chen, W.-Q. Changing profiles of cancer burden worldwide and in China: A secondary analysis of the global cancer statistics 2020. Chin. Med. J. (Engl). 134, 783–791 (2021).
pubmed: 33734139
pmcid: 8104205
doi: 10.1097/CM9.0000000000001474
Pienta, K. J. & Esper, P. S. Risk factors for prostate cancer. Ann. Intern Med. 118, 793–803 (1993).
pubmed: 8470854
doi: 10.7326/0003-4819-118-10-199305150-00007
Levine, E. G., King, R. A. & Bloomfield, C. D. The role of heredity in cancer. J. Clin. Oncol. 7, 527–540 (1989).
pubmed: 2647916
doi: 10.1200/JCO.1989.7.4.527
Nagase, H., Visse, R. & Murphy, G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc. Res. 69, 562–573 (2006).
pubmed: 16405877
doi: 10.1016/j.cardiores.2005.12.002
Roy, R., Yang, J. & Moses, M. A. Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. J. Clin. Oncol. 27, 5287–5297 (2009).
pubmed: 19738110
pmcid: 2773480
doi: 10.1200/JCO.2009.23.5556
Gobin, E. et al. A pan-cancer perspective of matrix metalloproteases (MMP) gene expression profile and their diagnostic/prognostic potential. BMC Cancer 19, 581 (2019).
pubmed: 31200666
pmcid: 6567474
doi: 10.1186/s12885-019-5768-0
Riddick, A. C. P. et al. Identification of degradome components associated with prostate cancer progression by expression analysis of human prostatic tissues. Br J Cancer 92, 2171–2180 (2005).
pubmed: 15928670
pmcid: 2361819
doi: 10.1038/sj.bjc.6602630
Trudel, D., Fradet, Y., Meyer, F., Harel, F. & Têtu, B. Membrane-type-1 matrix metalloproteinase, matrix metalloproteinase 2, and tissue inhibitor of matrix proteinase 2 in prostate cancer: Identification of patients with poor prognosis by immunohistochemistry. Hum. Pathol. 39, 731–739 (2008).
pubmed: 18329693
doi: 10.1016/j.humpath.2007.09.021
Miyake, H., Muramaki, M., Kurahashi, T., Takenaka, A. & Fujisawa, M. Expression of potential molecular markers in prostate cancer: Correlation with clinicopathological outcomes in patients undergoing radical prostatectomy. Urol. Oncol. 28, 145–151 (2010).
pubmed: 18848789
doi: 10.1016/j.urolonc.2008.08.001
Trudel, D., Fradet, Y., Meyer, F., Harel, F. & Têtu, B. Significance of MMP-2 expression in prostate cancer: An immunohistochemical study. Cancer Res. 63, 8511–8515 (2003).
pubmed: 14679018
Kessenbrock, K., Plaks, V. & Werb, Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell. 141, 52–67 (2010).
pubmed: 20371345
pmcid: 2862057
doi: 10.1016/j.cell.2010.03.015
Faivre, E. J. et al. Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer. Nature. 578, 306–310 (2020).
pubmed: 31969702
doi: 10.1038/s41586-020-1930-8
Rudzinski, J. K., Govindasamy, N. P., Lewis, J. D. & Jurasz, P. The role of the androgen receptor in prostate cancer-induced platelet aggregation and platelet-induced invasion. J. Thromb Haemost. 18, 2976–2986 (2020).
pubmed: 32692888
doi: 10.1111/jth.15020
Albayrak, S., Cangüven, Ö., Göktaş, C., Aydemir, H. & Köksal, V. Role of MMP-1 1G/2G promoter gene polymorphism on the development of prostate cancer in the Turkish population. Urol. Int. 79, 312–315 (2007).
pubmed: 18025848
doi: 10.1159/000109715
Sfar, S., Saad, H., Mosbah, F., Gabbouj, S. & Chouchane, L. TSP1 and MMP9 genetic variants in sporadic prostate cancer. Cancer Genet. Cytogenet. 172, 38–44 (2007).
pubmed: 17175378
doi: 10.1016/j.cancergencyto.2006.07.014
Dos Reis, S. T. et al. Polymorphisms of the matrix metalloproteinases associated with prostate cancer. Mol. Med. Rep. 1, 517–520 (2008).
pubmed: 21479442
Jacobs, E. J. et al. Polymorphisms in angiogenesis-related genes and prostate cancer. Cancer Epidemiol. Biomark. Prev. 17, 972–977 (2008).
doi: 10.1158/1055-9965.EPI-07-2787
Tsuchiya, N. et al. Clinical significance of a single nucleotide polymorphism and allelic imbalance of matrix metalloproteinase-1 promoter region in prostate cancer. Oncol. Rep. 22, 493–499 (2009).
pubmed: 19639194
doi: 10.3892/or_00000462
Srivastava, P., Lone, T. A., Kapoor, R. & Mittal, R. D. Association of promoter polymorphisms in MMP2 and TIMP2 with prostate cancer susceptibility in North India. Arch. Med. Res. 43, 117–124 (2012).
pubmed: 22374248
doi: 10.1016/j.arcmed.2012.02.006
Yaykaşli, K. O. et al. Polymorphisms in MMP-2 and TIMP-2 in Turkish patients with prostate cancer. Turk. J. Med. Sci. 44, 839–843 (2014).
pubmed: 25539555
doi: 10.3906/sag-1305-63
Adabi, Z. et al. Genetic polymorphism of MMP2 gene and susceptibility to prostate cancer. Arch. Med. Res. 46, 546–550 (2015).
pubmed: 26319608
doi: 10.1016/j.arcmed.2015.08.004
Shajarehpoor Salavati, L., Tafvizi, F. & Manjili, H. K. The association between MMP2 -1306 C > T (rs243865) polymorphism and risk of prostate cancer. Ir. J. Med. Sci. 186, 103–111 (2017).
pubmed: 27541146
doi: 10.1007/s11845-016-1492-9
Białkowska, K. et al. Association of zinc level and polymorphism in MMP-7 gene with prostate cancer in Polish population. PLoS One. 13, e0201065 (2018).
pubmed: 30036379
pmcid: 6056054
doi: 10.1371/journal.pone.0201065
Liao, C.-H. et al. The association of matrix metalloproteinase-1 promoter polymorphisms with prostate cancer in Taiwanese patients. Anticancer Res. 38, 3907–3911 (2018).
pubmed: 29970511
doi: 10.21873/anticanres.12675
Chen, L.-H. et al. Significant association of MMP2 promoter genotypes to asthma susceptibility in Taiwan. In Vivo 34, 3181–3186 (2020).
pubmed: 33144422
pmcid: 7811679
doi: 10.21873/invivo.12153
Kiani, A. et al. Activities and polymorphisms of MMP-2 and MMP-9, smoking, diabetes and risk of prostate cancer. Mol. Biol. Rep. 47, 9373–9383 (2020).
pubmed: 33165815
doi: 10.1007/s11033-020-05968-5
Liao, C.-H. et al. Association of matrix metalloproteinase-7 genotypes with prostate cancer risk. Anticancer Res. 43, 381–387 (2023).
pubmed: 36585199
doi: 10.21873/anticanres.16173
Higgins, J. P. T. & Thompson, S. G. Quantifying heterogeneity in a meta-analysis. Stat. Med. 21, 1539–1558 (2002).
pubmed: 12111919
doi: 10.1002/sim.1186
Mantel, N. & Haenszel, W. Statistical aspects of the analysis of data from retrospective studies of disease. J. Natl. Cancer Inst. 22, 719–748 (1959).
pubmed: 13655060
DerSimonian, R. & Laird, N. Meta-analysis in clinical trials. Control Clin. Trials. 7, 177–188 (1986).
pubmed: 3802833
doi: 10.1016/0197-2456(86)90046-2
Hayashino, Y., Noguchi, Y. & Fukui, T. Systematic evaluation and comparison of statistical tests for publication bias. J. Epidemiol. 15, 235–243 (2005).
pubmed: 16276033
pmcid: 7904376
doi: 10.2188/jea.15.235
Ekman, P. Genetic and environmental factors in prostate cancer genesis: Identifying high-risk cohorts. Eur. Urol. 35, 362–369 (1999).
pubmed: 10325490
doi: 10.1159/000019910
Grönberg, H., Damber, L. & Damber, J. E. Studies of genetic factors in prostate cancer in a twin population. J. Urol. 152, 1484–1487 (1994).
pubmed: 7933190
doi: 10.1016/S0022-5347(17)32452-7
Dianat, S. S. et al. Gene polymorphisms and prostate cancer: the evidence. BJU Int. 104, 1560–1572 (2009).
pubmed: 20053187
doi: 10.1111/j.1464-410X.2009.08973.x
Snyman, M. & Xu, S. The effects of mutations on gene expression and alternative splicing. Proc. Biol. Sci. 290, 20230565 (2023).
pubmed: 37403507
Einarsson, H. et al. Promoter sequence and architecture determine expression variability and confer robustness to genetic variants. Elife. 11, e80943 (2022).
pubmed: 36377861
pmcid: 9844987
doi: 10.7554/eLife.80943
Klijn, C. et al. A comprehensive transcriptional portrait of human cancer cell lines. Nat. Biotechnol. 33, 306–312 (2015).
pubmed: 25485619
doi: 10.1038/nbt.3080
Niland, S., Riscanevo, A. X. & Eble, J. A. Matrix metalloproteinases shape the tumor microenvironment in cancer progression. Int. J. Mol. Sci. 23, 146 (2021).
pubmed: 35008569
pmcid: 8745566
doi: 10.3390/ijms23010146
Roh, J., Muelleman, T., Tawfik, O. & Thomas, S. M. Perineural growth in head and neck squamous cell carcinoma: a review. Oral Oncol. 51, 16–23 (2015).
pubmed: 25456006
doi: 10.1016/j.oraloncology.2014.10.004
Zhang, K. et al. Association between MMP2-1306 C/T polymorphism and prostate cancer susceptibility: A meta-analysis based on 3906 subjects. Oncotarget 8, 45020–45029 (2017).
pubmed: 28445160
pmcid: 5546537
doi: 10.18632/oncotarget.16972
Meng, J. et al. Polymorphism of MMP-9 gene is not associated with the risk of urinary cancers: Evidence from an updated meta-analysis. Pathol. – Res. Pract. 214, 1966–1973 (2018).
pubmed: 30249503
doi: 10.1016/j.prp.2018.09.011
Liu, K. et al. The MMP2 rs243865 polymorphism increases the risk of prostate cancer: A meta-analysis. Oncotarget. 8, 72933–72938 (2017).
pubmed: 29069837
pmcid: 5641180
doi: 10.18632/oncotarget.18014
Weng, H., Zeng, X.-T., Wang, X.-H., Liu, T.-Z. & He, D.-L. Genetic association between matrix metalloproteinases gene polymorphisms and risk of prostate cancer: A meta-analysis. Front. Physiol. 8, 975 (2017).
pubmed: 29249982
pmcid: 5717537
doi: 10.3389/fphys.2017.00975
Zhou, H. & Zhu, X. Association between matrix-metalloproteinase polymorphisms and prostate cancer risk: A meta-analysis and systematic review. CMAR 10, 5247–5259 (2018).
doi: 10.2147/CMAR.S177551
Tikkinen, K. A. O. et al. Prostate cancer screening with prostate-specific antigen (PSA) test: A clinical practice guideline. BMJ 362, k3581 (2018).
pubmed: 30185545
pmcid: 6283372
doi: 10.1136/bmj.k3581
Ganguly, S. S. et al. Notch3 promotes prostate cancer-induced bone lesion development via MMP-3. Oncogene 39, 204–218 (2020).
pubmed: 31467432
doi: 10.1038/s41388-019-0977-1